New Triple-Threat attack on tough prostate cancer
NCT ID NCT07226986
Summary
This study is testing a new three-drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment combines an experimental drug (AMO959) with an approved targeted radiation therapy (AAA617) and a standard hormone-blocking pill. The goal is to see if this combination is safe and can better control the cancer in 123 men who have already tried one type of hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMalvern, Victoria, 3144, Australia
-
Novartis Investigative Site
RECRUITINGMurdoch, Western Australia, 6150, Australia
-
Novartis Investigative Site
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
RECRUITINGGranada, Andalusia, 18014, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Rio Grande Urology
RECRUITINGEl Paso, Texas, 79912, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.